explore | Grilled Cheese

📣 PRESENTING THE MAIN TOPICS OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm

Is multiple myeloma hereditary, environmental, or both? IMF Nurse Leadership Board member Beth Faiman explains in this short clip.

#AsktheIMF #mmsm

CAR T or bispecifics at early relapse? Omar Castaneda Puglianini, MD, of @moffittnews.bsky.social, breaks down considerations for treatment selection/sequencing as T-cell–redirecting therapies continue to move earlier in the myeloma treatment paradigm #mmsm #oncology www.onclive.com/view/earlier...

📣 #ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
ROUNDTABLE 1 “TOX and PRO”
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm

Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...

How are experts navigating subcutaneous therapy administrations in multiple myeloma? Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, break down newer patient-centric approaches #mmsm #oncology

Listen now: www.onclive.com/view/navigat...

🗞️ Just in: The phase 3 EXCALIBER-RRMM trial met its second dual primary end point, with iberdomide plus daratumumab/dexamethasone extending PFS vs DVd in patients with R/R multiple myeloma #mmsm #oncology

A real-world study from @moffittnews.bsky.social showed talquetamab produced similar response rates in patients with relapsed/refractory multiple myeloma, irrespective of whether they met the eligibility criteria for MonumenTAL-1 #mmsm #oncology

👀 NXC-201, a sterically optimized BCMA-directed CAR T-cell therapy, produced a high response rates in R/R AL amyloidosis, according to an interim update from the phase 1b/2 NEXICART-2 trial.

Full details 📰: www.onclive.com/view/nxc-201...

#oncology #mmsm

We're LIVE today at 7pm ET with myeloma specialist Dr. Douglas Sborov! Get ready to ask him all your myeloma questions as we close out #BloodCancerAwarenessMonth. Click "Going" on Facebook & turn on notifications to RSVP: https://www.facebook.com/events/1388778123259596/

#KnowMyeloma #mmsm

📣 ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm

In treating R/R #MMsm, BCMA-targeted CAR-T therapy prior to a bispecific antibody led to greater OS rates (79% vs. 63%) than did a bispecific antibody followed by CAR-T therapy, suggesting that such a sequencing strategy could improve survival probability: https://ow.ly/Q2X450ZRwY3

How can older myeloma patients decide what treatment is still worth pursuing? IMF NLB member Sam Shenoy answers and points to the IMF's free Decision-Making Tool at myeloma.org.

#AsktheIMF #KnowMyeloma #mmsm

The EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology

CHMP of the EMA issued a positive opinion supporting melflufen plus dexamethasone for the treatment of multiple myeloma after at least 2 prior lines of therapy that is refractory to lenalidomide and to the last line of therapy. #mmsm #oncology
www.onclive.com/view/chmp-re...

The latest version of the NCCN Guidelines for multiple myeloma include a dedicated section on MRD assessments with recommendations for clinical practice. Dive into the latest MRD updates and updated treatment recommendations #mmsm #oncology www.onclive.com/view/updated...

It's #BloodCancerAwarenessMonth!
No one piece of evidence can uncover myeloma. Doctors look at abnormal blood tests, lab numbers, imaging scans, and other specialty tests to diagnose it. Tell us: How did you or your team figure out you had myeloma?

#KnowMyeloma #mmsm

By 2034, 1 in 4 people diagnosed with myeloma will be African American. Knowing the early signs can be the key to timely diagnosis. Learn the symptoms to look for at knowmyeloma.org

#BloodCancerAwarenessMonth #mmsm #KnowMyeloma

📣 DISCOVER THE LEARNING OBJECTIVES OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm

📣 PROGRAMME HIGHLIGHT OF #ESHLYMPHOMA2026
3 simultaneous Meet-the-Expert sessions
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #MMsm #Lmsm